Therapeutically active compositions and their methods of use

Patent metadata

Field	Value
Publication number	US-9850277-B2
Application number	US-201615279146-A
Country	US
Kind code	B2
Filing date	Sep 28, 2016
Priority date	Jan 19, 2012
Publication date	Dec 26, 2017
Grant date	Dec 26, 2017

Abstract

Provided are methods of treating a cancer characterized by the presence of a mutant allele of IDH1/2 comprising administering to a subject in need thereof a compound described here.

First claim

The invention claimed is:

1. A compound which is:

or a pharmaceutically acceptable salt thereof.

2. A compound which is:

3. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

4. A pharmaceutical composition comprising a compound of claim 2 and a pharmaceutically acceptable carrier.

5. A method of treating a cancer characterized by an IDH1 mutation, wherein the method comprises administering to a subject in need thereof a therapeutically effective amount of a compound which is:

or a pharmaceutically acceptable salt thereof.

6. The method of claim 5 , wherein the IDH1 mutation is an IDH1 R132X mutation.

7. The method of claim 5 , wherein the IDH1 mutation is an IDH1 R132H mutation.

8. The method of claim 5 , wherein the IDH1 mutation is an IDH1 R132C mutation.

9. The method of claim 5 , wherein the cancer is glioma.

10. The method of claim 5 , wherein the cancer is glioblastoma.

11. The method of claim 5 , wherein the cancer is acute myelogenous leukemia (AML).

12. The method of claim 5 , wherein the cancer is cholangiocarcinoma.

13. The method of claim 5 , wherein the cancer is chondrosarcoma.

14. The method of claim 5 , wherein the cancer is myelodysplastic syndrome (MDS).

15. The method of claim 5 , wherein the cancer is myeloproliferative neoplasm (MPN).

16. The method of claim 5 , wherein the compound is:

Assignees

• Agios Pharmaceuticals Inc
• Agios Pharmaceuticals Inc

Inventors

• Popovici-Muller Janeta
• Lemieux Rene M
• Travins Jeremy
• Cai Zhenwei
• Cui Dawei
• Zhou Ding

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P19/08

  for bone diseases, e.g. rachitism, Paget's disease · CPC title